Navigation Links
Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure
Date:7/12/2010

PARSIPPANY, N.J., July 12 /PRNewswire/ -- Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), will sponsor Ed Randall's Bat for the Cure charity, in an effort to "strike-out prostate cancer" with awareness, education, effective management and prevention support at the organization's Minor League Baseball initiative across the country. FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer.

"We are honored to support Ed Randall's Bat for the Cure, which has done so much to educate the public about prostate cancer," said William Garbarini, Vice President, Orthopaedics and Urology Business Unit, Ferring Pharmaceuticals Inc.  "As the official charity of Minor League Baseball in 2010, Ed Randall's Bat for the Cure can build on its impressive record, increasing awareness among thousands of baseball fans. We are thrilled to help them get the word out."

Since 2002, Ed Randall's Bat for the Cure has worked to ensure that no man dies needlessly from prostate cancer due to lack of information about the disease. Ed Randall's Bat for the Cure educates men on the prevalence of prostate cancer (the most commonly diagnosed cancer in US men), and emphasizes the importance of early detection through screening.

From Boise to Jacksonville and many towns and cities in between, Ed Randall's Bat for the Cure spreads its message during Minor League Baseball games, distributing educational materials and offering free prostate cancer screenings.

"We are proud to partner with Ferring, whose product FIRMAGON is an important novel treatment option for locally advanced prostate cancer patients," said Ed Randall.  "Like us, Ferring encourages men to take a proactive role in their own health through education. We are happy to be on the same team, with the joint goal of striking out prostate cancer for good."

The latest statistics on prostate cancer are saddening: in the time it takes to complete a typical baseball game, more than 9 men, a team's starting lineup, will be impacted by the disease. Prostate cancer is the second-leading cause of cancer death among men with estimates of as many as 240,000 new cases of prostate cancer in the US this year. Overall, one in three men will develop a prostate problem, one in six will be diagnosed with prostate cancer, and for African-American men, 1 in 4 will develop the disease.

About Ed Randall's Bat for the Cure

Ed Randall's Bat for the Cure is a New York based charity raising prostate cancer awareness, promoting early PSA testing and raising much needed research funds to fight the disease. In 2009, the organization held Prostate Cancer Awareness Events at more than 130 Minor League games across the country. Free prostate cancer blood test screenings were also held at Yankee Stadium during a New York Yankees-Tampa Bay Rays game, separately at the Rays' Tropicana Field, at U.S. Cellular Field before a Chicago White Sox game, and at the United Center before a Chicago Bulls game.  Men received their blood work results within 2 weeks of the free tests and could then pursue further treatment with their family physician.

About FIRMAGON

FIRMAGON is a prescription medicine used in the treatment of advanced prostate cancer.

Important Safety Information

FIRMAGON should not be given to people who are allergic to any of the ingredients in FIRMAGON.  It should not be given to women who are pregnant or may become pregnant.  FIRMAGON can harm an unborn baby when given to a pregnant woman.

Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems, problems with balance of your body salts or electrolytes (such as, sodium, potassium, calcium, and magnesium), or have kidney or liver problems.

The common side effects of FIRMAGON  include: hot flashes, injection site pain, redness and swelling (especially with the first dose), weight gain, increase in some liver enzymes, tiredness, hypertension, back and joint pain, chills, urinary tract infection, and decreased sex drive and trouble with erectile function (impotence).

Please see Full Prescribing Information at www.Firmagon.com.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a Swiss-headquartered, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, reproductive health and urology. Ferring Pharmaceuticals offers a line of urology, infertility, gynecology, and orthopaedic products in the U.S. market. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com http://www.ferringusa.com/.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
5. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
6. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
7. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
8. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, ... to their offering. ... , The western blotting market ... 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
(Date:12/5/2016)... 5, 2016   BIOTRONIK today announced the ... study evaluates the safety and feasibility of performing the ... setting. BioMonitor 2 is an insertable cardiac ... placed underneath a patient,s skin to help physicians accurately ... fibrillation is a leading cause of stroke and heart ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... its latest transitional care facility – Avamere Transitional Care of Puget Sound ... foot short-term, post-acute health care center will provide patients recovering from illness or ...
(Date:12/5/2016)... St. Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... effects concussions have on the growing brains of young athletes. Over the course of ... to the head through unique mouth guards. The mouth guards, equipped with special sensors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):